The irAEs are consistent with 23ME-00610-mediated immune modulation. The data continue to support evaluation of 1400 mg 23ME-00610 Q3W (RP2D) in the ongoing Phase 2a.
Doses in the linear PK range demonstrated sustained peripheral target engagement and 23ME-00610 had a manageable safety profile. The clinical PK, PD, safety, and translational data support evaluation of 23ME-00610 1400 mg Q3W in the ongoing Phase 2a.
23ME-00610 induced T-cell cytokine production and enhanced T cell-mediated tumor cell killing in vitro. Blockade of the CD200:CD200R1 immune checkpoint inhibited tumor growth and engaged immune activation pathways in an S91 tumor cell model of melanoma in mice.
23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable PK and peripheral CD200R1 saturation. Increased immune-related AEs were observed at higher, pharmacologically relevant dose levels. Based on Phase 1 data, 1400 mg 23ME-00610 Q3W will be evaluated in Phase 2a.
The statistical analyses will primarily be descriptive. Participants reflecting the characteristics for the indication-specific cohorts with regards to age, sex, race, and ethnicity, including those from the Black, Latinx/Hispanic and Indigenous communities, will be prioritized for enrollment.